Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials

By afschroeder • August 22, 2025

Blasco A, López-Tarruella S, Urruticoechea A, Carrasco E, Spera G, Martín M, Bermejo B, Chap L, Ruiz-Borrego M, Crown J, García-Saenz JA, Chan A, Guerrero-Zotano Á, Semiglazov V, Calvo L, Pienkowski T, Herranz J, Slamon D. Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials. Oncologist. 2025 Aug 21:oyaf263. doi: 10.1093/oncolo/oyaf263. Epub ahead of print. PMID: 40838872.

Tags: adjuvant chemotherapy, breast cancer, Early-stage, Hematology/Oncology, Publications, surrogate endpoint

Lentivirus-Based Hematopoietic Stem/Progenitor Cell Therapy Provides Effective and Long-Term Treatment in Hypophosphatasia Mouse Model

Carrillo M, Tomer S, Wang L, Cook E, Wennerberg W, Tien N, Ng H, Alagarsamy J, Rezek V, Martin H, Narisawa S, Millan JL, Crine[...]

Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival

Marsh LA, Kim TH, Zhang M, Kubalanza K, Treece CL, Chase D, Memarzadeh S, Salani R, Karlan B, Rao J, Konecny GE. Pathologic response to[...]

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care

Brufsky AM, Finn RS, Metzger O, Goncalves R, Huang-Bartlett C, Sreenivasan S, Nur U, Davies J, Grigorenko A, Long GH. Comparative effectiveness of CDK4/6 inhibitors[...]